This paper examines informed consent as a foundational ethical and legal requirement in biomedical research and clinical trials. Drawing on FDA regulations (21 CFR §50) and ICH Good Clinical Practice (GCP) E6 guidelines, it outlines the purpose of informed consent, the mandatory and supplemental elements required in an informed consent form (ICF), and the standards for IRB approval and documentation. The paper also addresses practical guidance on how consent documents should be written to ensure genuine subject comprehension, including plain-language requirements, translation obligations, and the circumstances under which a subject must be excluded from a trial if consent cannot be properly obtained.
The paper demonstrates regulatory synthesis — it draws on two distinct regulatory frameworks (FDA 21 CFR and ICH GCP E6) and integrates them into a unified account of informed consent standards. Rather than summarizing one source at a time, the writer weaves them together to show where requirements overlap and reinforce each other, a skill central to compliance-oriented academic and professional writing.
The paper opens with a concise conceptual introduction defining informed consent and its role in clinical trials. It then dedicates a section to the purpose of consent, emphasizing subject autonomy and legal protection. The longest section enumerates mandatory and optional ICF elements drawn directly from regulatory text. The paper closes with practical guidance on writing style and plain-language communication, connecting legal obligation to real-world implementation. This structure moves effectively from theory to regulation to practice.
Informed consent is the basis of the transfer of information to a subject who is a candidate to participate in a clinical trial. The process of obtaining informed consent is a moral and ethical component of clinical trials conducted under Good Clinical Practices (GCPs). A subject is informed of all aspects of a clinical trial that are determined relevant to their decision to participate — including risks, trial purpose, and safety documentation — so that the subject can make a decision and confirm their willingness to participate. Informed consent precedes enrollment in a clinical trial and is documented by means of a written, signed, and dated consent form.
Except in a few narrow instances, such as life-threatening situations, all research involving any drug — including biological products, food additives, medical devices, or color additives — must take place with the legally effective informed consent of the subject of the clinical trial (21 CFR §50, 1998). All informed consent must be documented by means of an approved, written, signed, and dated informed consent form (ICH GCP E6, 1996).
The informed consent should consist of a template form that clearly identifies any research purpose for a study and includes all information the subject needs in order to decide whether or not to participate. This information must include any potential risks and benefits related to participating in the study. The subject should be able to completely understand all of the background information, and the purpose of the consent process cannot be to ask a subject to waive any legal rights. After reviewing the information contained in an IRB-approved informed consent document, a subject should be able to weigh all risks and benefits and decide whether or not to participate in the study.
The informed consent form (ICF) must be approved by the Institutional Review Board (IRB) for the site where clinical research is to take place. It is important to understand that the ICF is not a static document; it must be revised any time new information becomes available that is relevant to a subject's consent (ICH GCP E6, 1996), and any revisions must be reviewed and approved by the IRB. It is critical that no ICF documentation can cause a subject to waive any legal rights or release the investigator or sponsor from liability for negligence (21 CFR §50, 1998; ICH GCP E6, 1996).
The ICF must be written in a language that subjects can understand, with medical and technical terms explained. For patients who do not speak the language of the written ICF, a reviewed and documented translation must be provided (ICH GCP E6, 1996). The investigator should provide a signed and dated copy of the approved ICF to each subject, along with any supplemental documents or amendments to the information, prior to and during participation in the research.
The following elements are required for GCP compliance (21 CFR §50, 1998):
Informed consent remains the cornerstone of ethical biomedical research, ensuring that subjects can make a fully informed, voluntary decision about participation. Adherence to FDA regulations (21 CFR §50) and ICH GCP E6 standards protects both subjects and investigators throughout the research process, and the careful drafting of informed consent documents is essential to upholding these protections in practice.
You’re 48% through this paper. Sign up to read the remaining 2 sections.
Sign Up Now — Instant Access Already a member? Log inAlways verify citation format against your institution’s current style guide requirements.